$1.54 Billion is the total value of Avoro Capital Advisors LLC's 52 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMY | New | BRISTOL MYERS SQUIBB CO | $27,957,000 | – | 456,223 | +100.0% | 1.81% | – |
| TGTX | New | TG THERAPEUTICS INC | $27,015,000 | – | 3,294,463 | +100.0% | 1.75% | – |
| AZN | New | ASTRAZENECA PLCsponsored adr | $26,035,000 | – | 750,300 | +100.0% | 1.69% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $7,316,000 | – | 396,635 | +100.0% | 0.47% | – |
| BDSI | New | BIODELIVERY SCIENCE INTL | $7,285,000 | – | 2,469,488 | +100.0% | 0.47% | – |
| NLNK | New | NEWLINK GENETICS CORP | $6,451,000 | – | 795,412 | +100.0% | 0.42% | – |
| VRAY | New | VIEWRAY INC | $5,824,000 | – | 730,161 | +100.0% | 0.38% | – |
| CBIO | New | CATALYST BIOSCIENCES INC | $5,456,000 | – | 400,000 | +100.0% | 0.35% | – |
| INCY | New | INCYTE CORP | $4,736,000 | – | 50,000 | +100.0% | 0.31% | – |
| CLVS | New | CLOVIS ONCOLOGY INCcall | $264,000 | – | 675,000 | +100.0% | 0.02% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INCcall | $135,000 | – | 300,000 | +100.0% | 0.01% | – |
| MGNX | New | MACROGENICS INCcall | $37,000 | – | 14,500 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.